| Name | Title | Contact Details |
|---|
PTI Global Inc. is a Fremont, CA-based company in the Computers & Electronics sector.
Z-Communications, Inc. is a leading provider of VCO (voltage-controlled oscillators) and PLL (phase-locked loop) modules for the commercial RF and Wireless markets. With over 700 off-the-shelf products ranging from 40MHz to 10GHz bands, Z-Communications
Nanosys, Inc. is the leader in developing and delivering state-of-the-art Quantum Dot technology to the display industry. Nanosys proprietary QDEF® and QDOG™ technologies, key components of the Ultra High Definition (UHD) display revolution, are enabling a new generation of displays utilizing Quantum Dots to deliver vivid color, lifelike brightness and incredible power efficiency at a fraction of the cost of competing technologies. As of 2019, industry leading consumer electronics brands have shipped more than 10 million devices from tablets to monitors and TVs based on Nanosys` proprietary Quantum Dot technology. Founded in 2001, the company is headquartered in Silicon Valley, California where it operates the world`s largest Quantum Dot nanomaterials fab. Nanosys currently owns or has exclusive license rights to more than 350 issued and pending patents worldwide.
Engent is a Norcross, GA-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.